Terms: = Prostate cancer AND STAT5B, STAT5, 6777, ENSG00000173757, P51692
75 results:
1. stat5 induces androgen receptor (
Maranto C; Sabharwal L; Udhane V; Pitzen SP; McCluskey B; Qi S; O'Connor C; Devi S; Johnson S; Jacobsohn K; Banerjee A; Iczkowski KA; Wang L; Dehm SM; Nevalainen MT
Sci Adv; 2024 Mar; 10(9):eadi2742. PubMed ID: 38416822
[TBL] [Abstract] [Full Text] [Related]
2. PRL-mediated stat5b/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling.
Yang T; Chi Y; Wang X; Xu C; Chen X; Liu Y; Huang S; Zhu X; Zhang H; Zhuo H; Wu D
Cell Death Dis; 2024 Feb; 15(2):128. PubMed ID: 38341429
[TBL] [Abstract] [Full Text] [Related]
3. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for prostate cancer: The MIRAGE Randomized Clinical Trial.
Kishan AU; Ma TM; Lamb JM; Casado M; Wilhalme H; Low DA; Sheng K; Sharma S; Nickols NG; Pham J; Yang Y; Gao Y; Neylon J; Basehart V; Cao M; Steinberg ML
JAMA Oncol; 2023 Mar; 9(3):365-373. PubMed ID: 36633877
[TBL] [Abstract] [Full Text] [Related]
4. STAT3 and Its Pathways' Dysregulation-Underestimated Role in Urological Tumors.
Golus M; Bugajski P; Chorbińska J; Krajewski W; Lemiński A; Saczko J; Kulbacka J; Szydełko T; Małkiewicz B
Cells; 2022 Sep; 11(19):. PubMed ID: 36230984
[TBL] [Abstract] [Full Text] [Related]
5. Machine Learning-based Virtual Screening for STAT3 Anticancer Drug Target.
Wadood A; Ajmal A; Junaid M; Rehman AU; Uddin R; Azam SS; Khan AZ; Ali A
Curr Pharm Des; 2022; 28(36):3023-3032. PubMed ID: 35909285
[TBL] [Abstract] [Full Text] [Related]
6. GH Action in prostate cancer Cells Promotes Proliferation, Limits Apoptosis, and Regulates cancer-related Gene Expression.
Unterberger CJ; Maklakova VI; Lazar M; Arneson PD; Mcilwain SJ; Tsourkas PK; Hu R; Kopchick JJ; Swanson SM; Marker PC
Endocrinology; 2022 May; 163(5):. PubMed ID: 35383352
[TBL] [Abstract] [Full Text] [Related]
7. Assessment of stat5 as a potential therapy target in enzalutamide-resistant prostate cancer.
Erb HHH; Bodenbender J; Handle F; Diehl T; Donix L; Tsaur I; Gleave M; Haferkamp A; Huber J; Fuessel S; Juengel E; Culig Z; Thomas C
PLoS One; 2020; 15(8):e0237248. PubMed ID: 32790723
[TBL] [Abstract] [Full Text] [Related]
8. IL-15 in the Combination Immunotherapy of cancer.
Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
Front Immunol; 2020; 11():868. PubMed ID: 32508818
[TBL] [Abstract] [Full Text] [Related]
9. Neutrophils are mediators of metastatic prostate cancer progression in bone.
Costanzo-Garvey DL; Keeley T; Case AJ; Watson GF; Alsamraae M; Yu Y; Su K; Heim CE; Kielian T; Morrissey C; Frieling JS; Cook LM
Cancer Immunol Immunother; 2020 Jun; 69(6):1113-1130. PubMed ID: 32114681
[TBL] [Abstract] [Full Text] [Related]
10. Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy.
Shaw V; Srivastava S; Srivastava SK
Semin Cancer Biol; 2021 Jan; 68():75-83. PubMed ID: 31618686
[TBL] [Abstract] [Full Text] [Related]
11. Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant prostate cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors.
Udhane V; Maranto C; Hoang DT; Gu L; Erickson A; Devi S; Talati PG; Banerjee A; Iczkowski KA; Jacobsohn K; See WA; Mirtti T; Kilari D; Nevalainen MT
Mol Cancer Ther; 2020 Jan; 19(1):231-246. PubMed ID: 31548294
[TBL] [Abstract] [Full Text] [Related]
12. Positive stat5 Protein and Locus Amplification Status Predicts Recurrence after Radical prostatectomy to Assist Clinical Precision Management of prostate cancer.
Haddad BR; Erickson A; Udhane V; LaViolette PS; Rone JD; Kallajoki MA; See WA; Rannikko A; Mirtti T; Nevalainen MT
Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1642-1651. PubMed ID: 31292140
[TBL] [Abstract] [Full Text] [Related]
13. Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R).
Zhang Y; Gc S; Patel SB; Liu Y; Paterson AJ; Kappes JC; Jiang J; Frank SJ
Mol Cell Endocrinol; 2019 Jul; 492():110445. PubMed ID: 31100495
[TBL] [Abstract] [Full Text] [Related]
14. Role of Holmium laser enucleation of the prostate to increase cancer detection rate in patients with gray-zone PSA level.
Kim KH; Kim SW; Son HS; Kim DK; Jung DC; Kim HW; Kim JC; Hong SJ; Kim JH
Minerva Urol Nefrol; 2019 Feb; 71(1):72-78. PubMed ID: 30037211
[TBL] [Abstract] [Full Text] [Related]
15. Targeting the cellular schizophrenia. Likely employment of the antipsychotic agent pimozide in treatment of refractory cancers and glioblastoma.
Elmaci I; Altinoz MA
Crit Rev Oncol Hematol; 2018 Aug; 128():96-109. PubMed ID: 29958636
[TBL] [Abstract] [Full Text] [Related]
16. HSP27 is a partner of JAK2-stat5 and a potential therapeutic target in myelofibrosis.
Sevin M; Kubovcakova L; Pernet N; Causse S; Vitte F; Villeval JL; Lacout C; Cordonnier M; Rodrigues-Lima F; Chanteloup G; Mosca M; Chrétien ML; Bastie JN; Audia S; Sagot P; Ramla S; Martin L; Gleave M; Mezger V; Skoda R; Plo I; Garrido C; Girodon F; de Thonel A
Nat Commun; 2018 Apr; 9(1):1431. PubMed ID: 29650953
[TBL] [Abstract] [Full Text] [Related]
17. stat5A/B Blockade Sensitizes prostate cancer to Radiation through Inhibition of RAD51 and DNA Repair.
Maranto C; Udhane V; Hoang DT; Gu L; Alexeev V; Malas K; Cardenas K; Brody JR; Rodeck U; Bergom C; Iczkowski KA; Jacobsohn K; See W; Schmitt SM; Nevalainen MT
Clin Cancer Res; 2018 Apr; 24(8):1917-1931. PubMed ID: 29483142
[No Abstract] [Full Text] [Related]
18. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract] [Full Text] [Related]
19. Involvement of miR-106b in tumorigenic actions of both prolactin and estradiol.
Chen KE; Bustamante K; Nguyen V; Walker AM
Oncotarget; 2017 May; 8(22):36368-36382. PubMed ID: 28422740
[TBL] [Abstract] [Full Text] [Related]
20. ABL-N may induce apoptosis of human prostate cancer cells through suppression of KLF5, ICAM-1 and stat5b, and upregulation of Bax/Bcl-2 ratio: An in vitro and in vivo study.
Zhang Y; Liu K; Zhang Y; Qi J; Lu B; Shi C; Yin Y; Cai W; Li W
Oncol Rep; 2015 Dec; 34(6):2953-60. PubMed ID: 26397390
[TBL] [Abstract] [Full Text] [Related]
[Next]
